The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...

Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Denmark has achieved one of the goals of the Green Tripartite Agreement by designating 75,000 hectares of untouched forest. This is part of the broader plan to enhance biodiversity and allow nature to ...

Denmark is spending nearly 15 billion kroner to strengthen its defense in the Arctic and North Atlantic. This spending is part of a new agreement with the Faroese government and Greenland’s ...

and also has early-stage results for a next-generation candidate called amycretin. Pfizer recently selected a once-daily formulation of danuglipron as its candidate for phase 3 testing ...

JetBlue Airways (JBLU) saw its stock plunge a staggering 24% in early morning trading today after the airline issued a disappointing forecast for the first quarter, sending shockwaves through the ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...